These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16100546)

  • 1. [Treatment of overactive bladder].
    Hunskår S
    Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2029-30. PubMed ID: 16100546
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of overactive bladder].
    Schiøtz H
    Tidsskr Nor Laegeforen; 2005 Sep; 125(18):2525-6; author reply 2526. PubMed ID: 16186882
    [No Abstract]   [Full Text] [Related]  

  • 3. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solifenacin and darifenacin for overactive bladder.
    Obstet Gynecol; 2005 Aug; 106(2):401-2. PubMed ID: 16055596
    [No Abstract]   [Full Text] [Related]  

  • 5. [Anticholinergic treatment of overactive bladder. A costly treatment with doubtful clinical effect?].
    Møller LA; Lose G
    Ugeskr Laeger; 2003 Nov; 165(47):4552-3. PubMed ID: 14677238
    [No Abstract]   [Full Text] [Related]  

  • 6. Overactive bladder pharmacotherapy: what does the future hold?
    Dmochowski RR
    BJU Int; 2007 Jun; 99 Suppl 3():13-6. PubMed ID: 17488368
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmacological treatment of urinary incontinence.
    Andersson KE; Appell R; Cardozo LD; Chapple C; Drutz HP; Finkbeiner AE; Haab F; Vela Navarrete R
    BJU Int; 1999 Dec; 84(9):923-47. PubMed ID: 10571617
    [No Abstract]   [Full Text] [Related]  

  • 8. Solifenacin in the management of the overactive bladder syndrome.
    Robinson D; Cardozo L
    Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overactive bladder: drug therapy versus nerve stimulation.
    Pathak AS; Aboseif SR
    Nat Clin Pract Urol; 2005 Jul; 2(7):310-1. PubMed ID: 16474765
    [No Abstract]   [Full Text] [Related]  

  • 12. [Changes in muscarinic receptors of the aging bladder].
    Andersson KE; Schröder A
    Urologe A; 2004 May; 43(5):552-6. PubMed ID: 15098089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug therapy in urinary incontinence and/or bladder emptying problems].
    Møller LA; Abel I; Thyssen H; Sander P; Mouritsen L; Lose G; Sørensen C; Philipsen J; Ottesen M; Rasmussen FA; Topp M; Larsen J; Gimbel H
    Ugeskr Laeger; 2006 Jun; 168(26-32):2580-1; author reply 2581. PubMed ID: 16824423
    [No Abstract]   [Full Text] [Related]  

  • 14. PHARMAC responds on tolterodine for overactive bladder.
    Moodie P
    N Z Med J; 2005 Feb; 119(1229):U1871. PubMed ID: 16498471
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5-26.
    Okpara-Kamanu RI
    Eur Urol; 2005 Nov; 48(5):873-4. PubMed ID: 16137823
    [No Abstract]   [Full Text] [Related]  

  • 16. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
    Drinka PJ
    J Am Geriatr Soc; 2006 Jun; 54(6):1004-5. PubMed ID: 16776800
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diabetogenic bladder function diseases. Treatment in open studies with muscarinic receptor antagonists].
    Musch A
    Med Monatsschr Pharm; 2005 Sep; 28(9):329-30. PubMed ID: 16163888
    [No Abstract]   [Full Text] [Related]  

  • 19. Patients with overactive bladders deserve better.
    Brenner B; Rice M
    N Z Med J; 2006 Feb; 119(1229):U1846. PubMed ID: 16498474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.